|
|
|
|
|
Ropivacaine
drug data and news
Ropivacaine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Ropivacaine | ||
| Brand Names/Synonyms | Ropivacaine; Ropivacaine [INN]; Ropivacaina [Spanish]; Ropivacainum [INN-Latin]; Ropivacaina [INN-Spanish]; Naropin; S-Ropivacaine | ||
| Indication | Used in obstetric anesthesia and regional anesthesia for surgery | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Ropivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures. | ||
| Mechanism Of Action | Local anesthetics such as Ropivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. | ||
| Ropivacaine News (When available) |
| ||
| Dosage Forms | LIQUID; SOLUTION | ||
| Drug_Category | Anesthetics; Local Anesthetics; ATC:N01BB09 | ||
| Absorption | Not Available | ||
| Interactions | Interactions for Ropivacaine: Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. Cytochrome P4501A2 is involved in the formation of 3-hydroxy ropivacaine, the major metabolite. In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. Caution should be exercised when CYP1A2 inhibitors are coadministered. Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide | ||
| Chemical Formula | C17H26N2O | ||
| Molecular Weight | 274.401 g/mol | ||
| Smiles String | CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C | ||
| Melting Point | Not Available | ||
| Water Solubility | 57.6 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.537 | ||
| Isoelectric Point | 8.07 | ||
| Biotransformation | Hepatic | ||
| Half Life | ~4.2 hrs | ||
| Protein Binding [%] | 94%, mainly to a1-acid glycoprotein | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Ropivacaine.html http://www.rxlist.com/cgi/generic2/ropiva.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00492 | ||
| CAS Registry Number | 84057-95-4 | ||
| KEGG Compound ID | C07532 | ||
| PubChem ID | SID:213495 | ||
| PharmGKB ID | PA451271 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2229418 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |